Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | ENPP1 | P22413 | 3/20 | 0.43 |
| ▸ | PDE5A | O76074 | 6/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | PDE2A | O00408 | 1/20 | 0.39 |
| ▸ | PDE1A | P54750 | 1/20 | 0.39 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.39 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5242178 | 0.91 | ALDH1A1 (0.46) | ALDH1A1MEN1KMT2AMAPTENPP1 | |
| SCHEMBL13757314 | 0.77 | EPHB4 (0.39) | ALDH1A1ENPP1PDE5ACYP3A4ALOX15 | |
| SCHEMBL856422 | 0.74 | PDE5A (0.68) | ALDH1A1MEN1KMT2AMAPTENPP1 | |
| Hydrochloric Acid SCHEMBL6786207 | 0.73 | PDE5A (0.66) | ALDH1A1MEN1KMT2AMAPTENPP1 | |
| SCHEMBL5368533 | 0.72 | CYP3A4 (0.39) | ALDH1A1PDE5ACYP3A4ALOX15POLB | |
| SCHEMBL5243426 | 0.71 | PARP1 (0.43) | AURKACYP3A4ALOX15POLB | |
| SCHEMBL14671423 | 0.71 | POLB (0.50) | ALDH1A1MEN1KMT2AMAPTENPP1 | |
| SCHEMBL24392592 | 0.70 | ALDH1A1 (0.48) | ALDH1A1MEN1KMT2AMAPTENPP1 | |
| SCHEMBL19878150 | 0.70 | ALDH1A1 (0.48) | ALDH1A1MEN1KMT2AMAPTENPP1 | |
| SCHEMBL14407967 | 0.69 | MAPT (0.52) | ALDH1A1MEN1KMT2AMAPTAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7268142-B2 | Tetrahydroisoquinolinyl derivatives of quinazoline and isoquinoline | PFIZER INC. (US) | 2007-09-11 | — | — | US | disclosed |
| US-7268142-B2 | Tetrahydroisoquinolinyl derivatives of quinazoline and isoquinoline | PFIZER INC. (US) | 2007-09-11 | — | — | US | disclosed |
| US-7268142-B2 | Tetrahydroisoquinolinyl derivatives of quinazoline and isoquinoline | PFIZER INC. (US) | 2007-09-11 | — | — | US | disclosed |
| EP-1773805-A1 | QUINAZOLIN-4-YL-PIPERIDINE AND CINNOLIN-4-YL-PIPERIDINE DERIVATIVES AS PDE10 INHIBITORS FOR THE TREATMENT OF CNS DISORDERS | Pfizer Products Incorporated (US) | 2007-04-18 | — | — | EP | disclosed |
| EP-1723134-A2 | TETRAHYDROISOQUINOLINYL DERIVATIVES OF QUINAZOLINE AND ISOQUINOLINE | Pfizer Products Incorporated (US) | 2006-11-22 | — | — | EP | disclosed |
| WO-2006011040-A1 | QUINAZOLIN-4-YL- PIPERIDINE AND CINNOLIN-4-YL- PIPERIDINE DERIVATIVES AS PDE10 INHIBITORS FOR THE TREATMENT OF CNS DISORDERS | PFIZER PRODUCTS INC. (US) | 2006-02-02 | — | — | WO | disclosed |
| WO-2006011040-A1 | QUINAZOLIN-4-YL- PIPERIDINE AND CINNOLIN-4-YL- PIPERIDINE DERIVATIVES AS PDE10 INHIBITORS FOR THE TREATMENT OF CNS DISORDERS | PFIZER PRODUCTS INC. (US) | 2006-02-02 | — | — | WO | disclosed |
| US-20060019975-A1 | Novel piperidyl derivatives of quinazoline and isoquinoline | PFIZER INC | 2006-01-26 | — | — | US | disclosed |
| WO-2005082883-A2 | TETRAHYDROISOQUINOLINYL DERIVATIVES OF QUINAZOLINE AND ISOQUINOLINE | PFIZER PRODUCTS INC. (US) | 2005-09-09 | — | — | WO | disclosed |
| WO-2005082883-A2 | TETRAHYDROISOQUINOLINYL DERIVATIVES OF QUINAZOLINE AND ISOQUINOLINE | PFIZER PRODUCTS INC. (US) | 2005-09-09 | — | — | WO | disclosed |
| US-20050182079-A1 | Tetrahydroisoquinolinyl derivatives of quinazoline and isoquinoline | PFIZER INC | 2005-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182079-A1 | Tetrahydroisoquinolinyl derivatives of quinazoline and isoquinoline | PDE5A, PDE3A, PDE3B | ALDH1A1 1073/4885MEN1 2122/4885KMT2A 1767/4885 |
| US-20060019975-A1 | Novel piperidyl derivatives of quinazoline and isoquinoline | PDE5A, PDE4A, PDE3A | ALDH1A1 900/4885MEN1 3320/4885KMT2A 2191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.